The North America mRNA Synthesis & Manufacturing Market was valued at USD 1,900 Million in 2025 and is expected to reach USD 11,760 Million by 2035, growing at a compound annual growth rate (CAGR) of 20.1% from 2024 to 2035. The market leverages rapid advancements in biotechnology and the increasing adoption of mRNA therapeutics and vaccines. The presence of key industry players and robust research & development infrastructure further drives the growth of this sector.
The economic impact of tariffs on "North America mRNA Synthesis & Manufacturing Market".
Market Growth Drivers
Rising Demand for mRNA-Based Therapeutics: The increasing adoption of mRNA-based drugs for the treatment of infectious diseases, cancer, and genetic disorders acts as a major growth driver. Companies like Moderna are expanding their research pipeline, following the success of mRNA COVID-19 vaccines. Moderna's continuous innovation and collaborations with healthcare providers have enabled accelerated drug development, increasing the market potential for advanced mRNA synthesis and manufacturing technologies.
Strategic Partnerships and Investment in R&D: Significant investments and collaborations among leading biopharmaceutical companies and academia have accelerated innovations in mRNA manufacturing. For instance, Pfizer and BioNTech have invested heavily in expanding their manufacturing capabilities across North America. These partnerships are focused on improving large-scale, high-fidelity mRNA synthesis and ensuring robust supply chain efficiency, which is critical for rapid response to public health needs.
Market Trends
Expansion of Contract Development and Manufacturing Organizations (CDMOs): There is an evident shift as biopharma companies rely increasingly on specialized CDMOs such as Catalent and Thermo Fisher Scientific. These organizations offer expertise and infrastructure scaling, from pre-clinical to commercial production, and enable small and mid-sized pharma companies to accelerate their entry into the mRNA therapeutics market without the need for substantial initial capital investments.
Integration of Advanced Manufacturing Technologies: Market leaders are integrating automation, digitalization, and AI-driven analytics into mRNA manufacturing. Lonza has adopted digital twin technology and machine learning to optimize process consistency and product quality. This trend is reducing costs and minimizing human errors, reflecting a broader movement towards Industry 4.0 in bioprocessing and providing biomanufacturing agility necessary for personalized therapeutics.
Market Opportunity
Expansion into Non-Vaccine Therapeutics: The demonstrated safety and efficacy of mRNA in vaccines now opens the door for mRNA synthesis to be harnessed in protein replacement therapies, rare diseases, and oncology, providing ample growth opportunities for companies such as Arcturus Therapeutics, who are pioneering mRNA-based therapies for cystic fibrosis and solid tumors.
Government Funding and Pandemic Preparedness: Substantial government investments in pandemic readiness and biomedical innovation are driving growth. For instance, the U.S. government’s ongoing funding of mRNA platform innovation through agencies like BARDA is creating vast opportunities for industry participants to partner on novel therapeutic and vaccine solutions.
North America mRNA Synthesis & Manufacturing Market Revenue (USD Million), 2020-2035
The market revenue chart shows a robust upward trajectory from USD 500 Million in 2020 to an estimated USD 11,760 Million by 2035. Early growth was driven by the deployment of COVID-19 vaccines, and revenues accelerated further with expanding therapeutic applications in oncology and rare diseases. The chart indicates a CAGR of over 20% during the forecast period, reflecting sustained industry investments, government support for biopreparedness, and new entrant innovations. Revenue is projected to stabilize at a high level by 2035 as mRNA platforms become more established.
North America mRNA Synthesis & Manufacturing Market by Region Share (%), 2025
In 2025, the United States dominates the North American mRNA Synthesis & Manufacturing Market, accounting for 73% of market share due to its strong R&D infrastructure, manufacturing bases, and regulatory support. Canada follows with 16%, supported by government innovation funding and a growing life sciences sector. Mexico holds a smaller share of 6% as it scales up its biomanufacturing capabilities. Other regions, including Puerto Rico and Rest of North America, hold 3% and 2%, respectively, reflecting emerging contributions to regional supply chain and contract manufacturing.
Recent Developments in North America mRNA Synthesis & Manufacturing Market (Last 6 Months)
In January 2024, Moderna announced the groundbreaking of a new mRNA manufacturing facility in Toronto, Canada, aiming to expand its vaccine and therapeutic production capacity in North America. The new facility is projected to increase regional supply security and enhance rapid response capabilities for future pandemics.
In March 2024, Thermo Fisher Scientific launched a next-generation mRNA synthesis platform focused on scalable, high-purity manufacturing. This platform leverages AI-driven process analytics and automation, enabling partners to more rapidly advance mRNA vaccine candidates from development to clinical trial supply.
In April 2024, Pfizer disclosed a partnership with the U.S. Department of Health and Human Services to enhance mRNA platform research and pandemic preparedness. The collaboration focuses on expanding mRNA supply chain resilience and funding next-generation mRNA therapies for infectious diseases beyond COVID-19.
Press Releases